UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.207

Sortiert nach

Drug‐induced liver injury: Advances in mechanistic understanding that will inform risk management

Clinical pharmacology and therapeutics, 2017-04, Vol.101 (4), p.469-480

2017

Volltextzugriff (PDF)

Case Definition and Phenotype Standardization in Drug-Induced Liver Injury

Clinical pharmacology and therapeutics, 2011-06, Vol.89 (6), p.806-815

2011

Volltextzugriff (PDF)

Drug Safety Sciences and the Bottleneck in Drug Development

Clinical pharmacology and therapeutics, 2011-06, Vol.89 (6), p.788-790

Watkins, PB

2011

Volltextzugriff (PDF)

Use of Pharmaco-Metabonomics for Early Prediction of Acetaminophen-Induced Hepatotoxicity in Humans

Clinical pharmacology and therapeutics, 2010-07, Vol.88 (1), p.45-51

2010

Volltextzugriff (PDF)

The Application of Metabonomics to Predict Drug-Induced Liver Injury

Clinical pharmacology and therapeutics, 2010-09, Vol.88 (3), p.394-399

2010

Volltextzugriff (PDF)

The Effects of Heparins on the Liver: Application of Mechanistic Serum Biomarkers in a Randomized Study in Healthy Volunteers

Clinical pharmacology and therapeutics, 2012-08, Vol.92 (2), p.214-220

2012

Volltextzugriff (PDF)

MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and Bioenergetics

Pharmaceutical research, 2015-06, Vol.32 (6), p.1975-1992

2015

Volltextzugriff (PDF)

Comparative analysis of portal hepatic infiltrating leucocytes in acute drug‐induced liver injury, idiopathic autoimmune and viral hepatitis

Clinical and experimental immunology, 2015-04, Vol.180 (1), p.40-51

2015

Volltextzugriff (PDF)

Interactions between seabirds and deep-water hake trawl gear: an assessment of impacts in South African waters

Animal conservation, 2008-08, Vol.11 (4), p.247-254

2008

Volltextzugriff (PDF)

Serum proteomic profiling in patients with drug-induced liver injury

Alimentary pharmacology & therapeutics, 2012-03, Vol.35 (5), p.600-612

2012

Volltextzugriff (PDF)

Blood gene expression signatures predict exposure levels

Proceedings of the National Academy of Sciences - PNAS, 2007-11, Vol.104 (46), p.18211-18216

2007

Volltextzugriff (PDF)

Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials

Clinical pharmacology and therapeutics, 2017-12, Vol.102 (6), p.961-969

2017

Volltextzugriff (PDF)

Systems pharmacology modeling of drug‐induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters

Clinical pharmacology and therapeutics, 2017-04, Vol.101 (4), p.501-509

2017

Volltextzugriff (PDF)

Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym®, a Mechanistic Model of Drug‐Induced Liver Injury

CPT: pharmacometrics and systems pharmacology, 2016-01, Vol.5 (1), p.31-39

2016

Volltextzugriff (PDF)

Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen

Clinical pharmacology and therapeutics, 2016-04, Vol.99 (4), p.432-441

2016

Volltextzugriff (PDF)

Metabolomics in toxicology: preclinical and clinical applications

Toxicological sciences, 2011-03, Vol.120 Suppl 1 (Supplement 1), p.S146-S170

2011

Volltextzugriff (PDF)

Hepatic Dysfunction Associated with Troglitazone

The New England journal of medicine, 1998-03, Vol.338 (13), p.916-917

1998

Volltextzugriff (PDF)

Managing the Risk of Drug-Induced Liver Injury

Clinical pharmacology and therapeutics, 2013-12, Vol.94 (6), p.629-631

Watkins, P B

2013

Volltextzugriff (PDF)

Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid-Mediated Troglitazone Hepatotoxicity

Clinical pharmacology and therapeutics, 2014-11, Vol.96 (5), p.589-598

2014

Volltextzugriff (PDF)

Role of intestinal P-glycoprotein ( ) in interpatient variation in the oral bioavailability of cyclosporine

Clinical pharmacology and therapeutics, 1997-09, Vol.62 (3), p.248-260

1997

Volltextzugriff (PDF)

A Mechanistic Model of Drug‐Induced Liver Injury Aids the Interpretation of Elevated Liver Transaminase Levels in a Phase I Clinical Trial

CPT: pharmacometrics and systems pharmacology, 2014-02, Vol.3 (2), p.1-8

2014

Volltextzugriff (PDF)

The Effect of an Individual’s Cytochrome CYP3A4 Activity on Docetaxel Clearance

Clinical cancer research, 2000-04, Vol.6 (4), p.1255-1258

2000

Volltextzugriff (PDF)

Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid–Mediated DILI

CPT: pharmacometrics and systems pharmacology, 2014-07, Vol.3 (7), p.1-8

2014

Volltextzugriff (PDF)

Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes

The Journal of clinical investigation, 1992-11, Vol.90 (5), p.1871-1878

1992

Volltextzugriff (PDF)

Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test

Drug metabolism and disposition, 1994-11, Vol.22 (6), p.947

1994

Volltextzugriff (PDF)

1 – 25 von 2.207

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.009)
Mit Volltextzugriff
(1.946)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.437)
Life Sciences & Biomedicine
(1.009)
Humans
(787)
Biological And Medical Sciences
(498)
Male
(463)
Female
(424)
Medical Sciences
(349)
Animals
(326)
Physical Sciences
(317)
Middle Aged
(258)
Adult
(250)
Physics
(240)
Fundamental And Applied Biological Sciences. Psychology
(171)
Aged
(169)
Exact Sciences And Technology
(116)
Technology
(115)
Physics, Particles & Fields
(107)
Biochemistry & Molecular Biology
(104)
Pharmacology & Pharmacy
(104)
Pharmacology. Drug Treatments
(102)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Drug‐induced liver injury: Advances in mechanistic understanding that will inform risk management

Case Definition and Phenotype Standardization in Drug-Induced Liver Injury

Drug Safety Sciences and the Bottleneck in Drug Development

Use of Pharmaco-Metabonomics for Early Prediction of Acetaminophen-Induced Hepatotoxicity in Humans

The Application of Metabonomics to Predict Drug-Induced Liver Injury

The Effects of Heparins on the Liver: Application of Mechanistic Serum Biomarkers in a Randomized Study in Healthy Volunteers

MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and Bioenergetics

Comparative analysis of portal hepatic infiltrating leucocytes in acute drug‐induced liver injury, idiopathic autoimmune and viral hepatitis

Interactions between seabirds and deep-water hake trawl gear: an assessment of impacts in South African waters

Serum proteomic profiling in patients with drug-induced liver injury

Blood gene expression signatures predict exposure levels

Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials

Systems pharmacology modeling of drug‐induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters

Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym®, a Mechanistic Model of Drug‐Induced Liver Injury

Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen

Metabolomics in toxicology: preclinical and clinical applications

Hepatic Dysfunction Associated with Troglitazone

Managing the Risk of Drug-Induced Liver Injury

Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid-Mediated Troglitazone Hepatotoxicity

Role of intestinal P-glycoprotein ( ) in interpatient variation in the oral bioavailability of cyclosporine

A Mechanistic Model of Drug‐Induced Liver Injury Aids the Interpretation of Elevated Liver Transaminase Levels in a Phase I Clinical Trial

The Effect of an Individual’s Cytochrome CYP3A4 Activity on Docetaxel Clearance

Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid–Mediated DILI

Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes

Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test

Suchergebnisse filtern